Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 19/20 | 1.00 |
| ▸ | MMP9 | P14780 | 19/20 | 1.00 |
| ▸ | MMP14 | P50281 | 13/20 | 1.00 |
| ▸ | MMP1 | P03956 | 13/20 | 1.00 |
| ▸ | MMP3 | P08254 | 13/20 | 1.00 |
| ▸ | MMP13 | P45452 | 10/20 | 1.00 |
| ▸ | MMP7 | P09237 | 1/20 | 0.69 |
| ▸ | MMP8 | P22894 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MMP16 | P51512 | 1/20 | 0.52 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27812748 | 0.94 | MMP2 (1.00) | MMP2MMP9MMP14MMP1MMP3 | |
| SCHEMBL1785737 | 0.94 | MMP2 (1.00) | MMP2MMP9MMP14MMP1MMP3 | |
| SCHEMBL1783672 | 0.86 | MMP2 (1.00) | MMP2MMP9MMP14MMP1MMP3 | |
| SCHEMBL1783733 | 0.82 | MMP2 (1.00) | MMP2MMP9MMP14MMP1MMP3 | |
| SCHEMBL12650697 | 0.81 | MMP2 (0.81) | MMP2MMP9MMP14MMP1MMP3 | |
| SCHEMBL18193637 | 0.81 | MMP2 (0.79) | MMP2MMP9MMP14MMP1MMP3 | |
| SCHEMBL1784722 | 0.81 | MMP2 (1.00) | MMP2MMP9MMP14MMP1MMP3 | |
| SCHEMBL1784721 | 0.81 | MMP2 (1.00) | MMP2MMP9MMP14MMP1MMP3 | |
| SCHEMBL12609305 | 0.80 | MMP2 (0.81) | MMP2MMP9MMP14MMP1MMP3 | |
| SCHEMBL12609294 | 0.80 | MMP2 (0.81) | MMP2MMP9MMP14MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2320954-B1 | DIAGNOSTIC AGENTS SELECTIVE AGAINST METALLOPROTEASES | BRACCO IMAGING SPA (IT) | 2019-09-04 | — | — | EP | disclosed |
| US-9480758-B2 | Diagnostic agents selective against metalloproteases | BRACCO IMAGING S.P.A. (IT) | 2016-11-01 | — | — | US | disclosed |
| US-8329751-B2 | Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors | BRACCO IMAGING S.P.A. (IT) | 2012-12-11 | — | — | US | disclosed |
| US-20110124653-A1 | ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS | BRACCO IMAGING S.P.A. (IT) | 2011-05-26 | — | — | US | disclosed |
| EP-2323998-A1 | ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS | Bracco Imaging S.p.A (IT) | 2011-05-25 | — | — | EP | disclosed |
| US-20110117015-A1 | Diagnostic Agents Selective Against Metalloproteases | BRACCO IMAGING S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20100087505-A1 | Compounds Having Aryl-Sulphonamidic Structure Useful As Metalloproteases Inhibitors | BRACCO IMAGING S.P.A. (IT) | 2010-04-08 | — | — | US | disclosed |
| EP-2149568-A1 | ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS | Bracco Imaging S.p.A (IT) | 2010-02-03 | — | — | EP | disclosed |
| WO-2010010080-A1 | ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS | BRACCO IMAGING SPA (IT) | 2010-01-28 | — | — | WO | disclosed |
| EP-2147684-A1 | Diagnostic Agents Selective Against Metalloproteases | Bracco Imaging S.p.A (IT) | 2010-01-27 | — | — | EP | disclosed |
| EP-1972617-A1 | Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors | Bracco Imaging, S.P.A. (IT) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124653-A1 | ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS | MMP9, MMP1, MMP2 | MMP2 3/4885MMP9 1/4885MMP14 33/4885 |
| US-20110117015-A1 | Diagnostic Agents Selective Against Metalloproteases | MMP3, MMP7, MMP9 | MMP2 9/4885MMP9 3/4885MMP14 20/4885 |
| US-20100087505-A1 | Compounds Having Aryl-Sulphonamidic Structure Useful As Metalloproteases Inhibitors | MMP9, MMP1, ARSA | MMP2 9/4885MMP9 1/4885MMP14 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.